Radiotherapy in Prostate Cancer

Radiotherapy is one of the major treatment options for prostate cancer. Depending on the stage, risk group, age, symptoms, and overall treatment goals, it may be used as definitive treatment, after surgery, for recurrence, or for symptom control in advanced disease. The most appropriate approach varies from person to person, which is why radiation should be understood as one part of a broader treatment discussion rather than a single fixed pathway. ^[1][2][3]

In which situations is it preferred?

Radiotherapy may be chosen as a primary treatment for localized prostate cancer, as adjuvant or salvage treatment after prostatectomy, or as part of management for locally advanced or selected metastatic settings. It may also be combined with androgen-deprivation therapy in some risk groups. The decision depends on tumor characteristics, PSA, Gleason grade group, imaging findings, urinary baseline symptoms, age, and patient priorities. ^[1][2][4]

Some patients are candidates for external-beam radiotherapy, some for brachytherapy, and some for combination approaches. Others may be better served by active surveillance or surgery. There is no universally superior choice that fits every prostate cancer diagnosis. ^[2][3][4]

How is treatment planning performed?

Planning usually includes imaging, target definition, assessment of nearby structures such as bladder and rectum, and discussion of whether hormonal therapy is needed. Modern radiation oncology aims to deliver treatment accurately while reducing dose to normal tissues as much as possible. Even so, precision does not eliminate side effects completely. ^[1][2][5]

The treatment schedule depends on the chosen regimen. Some patients receive conventionally fractionated treatment, while others may receive moderate hypofractionation or other evidence-based schedules. The exact plan reflects both the cancer characteristics and the center’s protocol. ^[1][2][5]

What side effects are possible?

Potential side effects may involve urinary symptoms, bowel irritation, fatigue, sexual side effects, and, less commonly, longer-term tissue effects. The pattern and severity vary according to technique, total dose, anatomy, baseline function, and whether other treatments are being used at the same time. ^[1][2][4]

It is helpful to distinguish between short-term treatment effects and later complications. Some men experience temporary urinary urgency or bowel frequency during treatment, while others are more concerned about long-term erectile dysfunction or persistent rectal symptoms. Quality-of-life discussion is therefore a necessary part of planning, not an optional extra. ^[2][4][5]

Why is follow-up important?

Follow-up is essential because response is monitored over time, often through PSA trends, symptoms, examination, and imaging when indicated. PSA after radiotherapy behaves differently from PSA after prostatectomy, so patients should not expect the same pattern. Temporary fluctuations may occur, and interpretation should be left to the treating team. ^[1][2][5]

Follow-up also helps identify persistent urinary or bowel toxicity, sexual side effects, and possible recurrence. The purpose is not only to look for cancer control but also to manage survivorship and quality of life. ^[2][4][5]

Why should quality of life be discussed when choosing treatment?

Because different treatments affect daily life differently. For some men, avoiding surgery is important; for others, the pattern of urinary, bowel, or sexual side effects matters more. Shared decision-making helps align the treatment choice with the patient’s values, expectations, work demands, and tolerance for uncertainty. ^[2][3][4]

What is the patient’s role after treatment?

Patients play an important role by attending follow-up visits, reporting ongoing or worsening symptoms, tracking PSA as advised, and discussing changes in urination, bowel function, sexual health, or bone pain when relevant. The treatment journey does not end when radiation sessions finish. ^[1][2][5]

Which symptoms during follow-up matter most?

Persistent or worsening urinary obstruction, visible bleeding, significant rectal bleeding, severe pain, unexplained weight loss, new bone pain, or other concerning symptoms should be reviewed promptly. Not all such symptoms indicate recurrence, but they should not be ignored. ^[2][4][5]